Xylo<wbr/>metazoline (hydro<wbr/>chloride)

Xylometazoline (hydrochloride)

CAT N°: 27797
Price:

From 48.00 40.80

Xylometazoline is an ?-adrenergic receptor (?-AR) agonist that binds to ?1A-, ?1B-, ?1D-, ?2A-, ?2B-, and ?2C-ARs in a radioligand binding assay (IC50s = 0.08, 0.56, 0.45, 0.98, 1.8, and 0.22 ?M, respectively).{51089} It increases intracellular calcium levels in HEK293 cells transfected with human ?2B-ARs (EC50 = 99 ?M) but not other ?-ARs. Xylometazoline is also an agonist of the serotonin (5-HT) receptor subtype 5-HT1 (Kis = 0.7 and 14 nM for the human 5-HT1D and 5-HT1B receptors, respectively).{51090} It inhibits forskolin-induced cAMP production in CHO Pro 5 cells expressing human 5-HT1D and 5-HT1B receptors by 62 and 49%, respectively, when used at a concentration of 1 ?M. Xylometazoline (0.25 ?g/ml) induces contraction of isolated dog nasal mucosal blood vessels and reduces nasal patency in dogs when administered topically or intravenously.{51091}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]methyl]-4,5-dihydro-1H-imidazole, monohydrochloride
  • Correlated keywords
    • 526-36-3 8057-34-9 28096-10-8 Galazolin Neo-Rinoleina Novorin Olynth Otrivin Otrivine Oxymetalozine Rhinex Rhinostop Therapin Xymelin Brizolin Synephrine II ?AR HEK 293 5HT 5HT1 5HT1D 5HT1B Pro5
  • Product Overview:
    Xylometazoline is an ?-adrenergic receptor (?-AR) agonist that binds to ?1A-, ?1B-, ?1D-, ?2A-, ?2B-, and ?2C-ARs in a radioligand binding assay (IC50s = 0.08, 0.56, 0.45, 0.98, 1.8, and 0.22 ?M, respectively).{51089} It increases intracellular calcium levels in HEK293 cells transfected with human ?2B-ARs (EC50 = 99 ?M) but not other ?-ARs. Xylometazoline is also an agonist of the serotonin (5-HT) receptor subtype 5-HT1 (Kis = 0.7 and 14 nM for the human 5-HT1D and 5-HT1B receptors, respectively).{51090} It inhibits forskolin-induced cAMP production in CHO Pro 5 cells expressing human 5-HT1D and 5-HT1B receptors by 62 and 49%, respectively, when used at a concentration of 1 ?M. Xylometazoline (0.25 ?g/ml) induces contraction of isolated dog nasal mucosal blood vessels and reduces nasal patency in dogs when administered topically or intravenously.{51091}

We also advise you